Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01922037 · ClinicalTrials.gov registry record · Phase 4
A Study in Participants With Asthma Initiating Treatment With Omalizumab (Xolair)
A Phase 4 study of Asthma, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 4
- Development phase
- 806
- Enrollment target
- 20
- Study locations
NCT01922037: Completed Phase 4 study of Asthma, sponsored by Hoffmann-La Roche.
NCT01922037 is a Phase 4 study of Asthma that has completed, run by Hoffmann-La Roche. The registered enrollment target is 806 participants, below the 1,561-participant average among 374 other Asthma trials with a reported enrollment target (48% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01922037, a Phase 4 study of Asthma, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 806 participants
- Enrollment target
- 20
- Study locations
Study Summary
This multicenter, prospective study will evaluate the baseline participant characteristics (including biomarkers) associated with a variety of individual and composite clinical outcomes in participants with moderate to severe asthma initiating treatment with omalizumab.
Primary Outcome
An asthma exacerbation was defined as new or increased asthma symptoms which resulted in either hospitalization and/or treatment with systemic corticosteroids (or increase of stable maintenance dose) for \>/= 3 days.
Conditions Studied
Interventions
- DRUG Omalizumab
Study Locations (20)
California
- Stuart Epstein MD - PP - Beverly Hills
- West Coast Clinical Trials Global, LLC - Costa Mesa
- Peninsula Allergy Associates - Daly City
- Allianz Medical and Research Center - Fountain Valley
- William Ebbeling MD - PP - Fresno
- Gettysburg Medical Clinic - Fresno
- Allergy & Asthma Inst Valley - Granada Hills
- VA Loma Linda Healthcare System - Loma Linda
- Allergy Asthma Care Ctr, Inc. - Los Angeles
- Southern California Research Center - Mission Viejo
- North Bay Allergy & Asthma; Medical Assoc - Napa
- Choc Psf, Amc - Orange
Arizona
- San Tan Allergy & Asthma - Gilbert
- Dedicated Clinical Research - Goodyear
- Allergy Associates of Tucson - Tucson
- University of Arizona - Tucson
Alabama
- Alabama Allergy & Asthma - Birmingham
- Achieve Clinical Research, LLC - Birmingham
- Huntsville Lung Associates PC - Huntsville
Arkansas
- Little Rock Allergy & Asthma; Clinical Research Center - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 806 participants |
| Start Date | 2013-06-19 |
| Est. Completion | 2016-03-31 |
| Phase | Phase 4 |
What the finished NCT01922037 record still lists
NCT01922037 is an interventional study that assigns participants to a tested intervention. The registered 806 participants enrollment target is mid-sized for trials with a published cap, below the 1,561-participant average among 374 other Asthma trials with a reported enrollment target (48% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 1 intervention - of which Omalizumab is the first listed.
NCT01922037 names 20 study sites across 4 states, led by California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT01922037 about?
NCT01922037 is a clinical study titled "A Study in Participants With Asthma Initiating Treatment With Omalizumab (Xolair)". This multicenter, prospective study will evaluate the baseline participant characteristics (including biomarkers) associated with a variety of individual and composite clinical outcomes in participants with moderate to severe asthma initiating treatment with omalizumab.
What is the current status of trial NCT01922037?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 806 participants. The study started on 2013-06-19. Estimated completion is 2016-03-31.
What conditions does trial NCT01922037 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT01922037?
The interventions under investigation include: Omalizumab (DRUG).
Who is sponsoring clinical trial NCT01922037?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01922037 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01922037's enrollment target sits among peer trials
806 53rd of 374 higher than 322 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
RECRUITING · Phase 4
-
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 4
-
Viral Infection in Asthma (VIA) Study
RECRUITING · Phase 4
-
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
RECRUITING · Phase 4
-
The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)
RECRUITING · Phase 4
-
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04613596 · 806 participants · Phase 2
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- NCT06065098 · 806 participants · NA
Church-based Health Intervention to Eliminate Racial Inequalities in Cardiovascular Health
- NCT06529094 · 808 participants · NA
Implementing a Decision Support Tool to Prevent Community-Acquired Pressure Injury in Spinal Cord Injury (SCI) in the Spinal Cord Injury Clinic
- NCT04423211 · 804 participants · Phase 3
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI